Publications by authors named "William Sandborn"

Claim this Profile
A
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
Jurij Hanžel, Virginia Solitano, Sudheer Kumar Vuyyuru, Remo Panaccione, Bruce E Sands, William J Sandborn

Gastroenterology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies.
Stefan Schreiber, Jean-Frederic Colombel, Stephen B Hanauer, William J Sandborn, Silvio Danese

Inflamm Bowel Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).
Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber, Silvio Danese, Maria Kłopocka

J Crohns Colitis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's Disease.
Reena Khanna, Brian G Feagan, Guangyong Zou, Larry W Stitt, John W D McDonald, William J Sandborn

Inflamm Bowel Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
Bruce E Sands, Remo Panaccione, Geert D'Haens, Stefan Schreiber, Vipul Jairath, William J Sandborn

Lancet Gastroenterol Hepatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Genetic Risk, Dysbiosis, and Treatment Stratification Using Host Genome and Gut Microbiome in Inflammatory Bowel Disease.
Ahmed Moustafa, Weizhong Li, Ericka L Anderson, Emily H MWong, Parambir S Dulai, William J Sandborn

Clin Transl Gastroenterol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
Stephen B Hanauer, Bruce E Sands, Stefan Schreiber, Silvio Danese, Maria Kłopocka, William J Sandborn

Gastroenterology· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A living organoid biobank of patients with Crohn's disease reveals molecular subtypes for personalized therapeutics.
Courtney Tindle, Ayden G Fonseca, Sahar Taheri, Gajanan D Katkar, Jasper Lee, William J Sandborn

Cell Rep Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab Therapy.
Rochelle Wong, Paris Charilaou, Amy Hemperly, Lihui Qin, Yushan Pan, William J Sandborn

Crohns Colitis 360· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis.
Mina Hassan-Zahraee, Zhan Ye, Li Xi, Elizabeth Dushin, Julie Lee, William J Sandborn

J Crohns Colitis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
Subrata Ghosh, Brian G Feagan, Elyssa Ott, Christopher Gasink, Bridget Godwin, William J Sandborn

J Crohns Colitis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practice.
Dominik Bettenworth, Mark E Baker, Joel G Fletcher, Vipul Jairath, Cathy Lu, William J Sandborn

Nat Rev Gastroenterol Hepatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pangenome comparison of genomospecies unveils genetic diversity and ecological insights.
Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, Chia-Yun Hsu, Caitlin Tribelhorn, William J Sandborn

mSystems· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
Andres J Yarur, Michael V Chiorean, Julián Panés, Vipul Jairath, Jinkun Zhang, William J Sandborn

J Crohns Colitis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathogenic strains can emerge from gut-resident commensals.
Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, Maxwell J Neal, Mousumi Paulchakrabarti, William J Sandborn

bioRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
Waqqas Afif, Ramesh P Arasaradnam, Maria T Abreu, Silvio Danese, William J Sandborn

Am J Gastroenterol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
Séverine Vermeire, Silvio Danese, William J Sandborn, Stefan Schreiber, Stephen Hanauer

J Crohns Colitis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
Geert D'Haens, Filip Baert, Silvio Danese, Taku Kobayashi, Edward V Loftus, William J Sandborn

Eur J Gastroenterol Hepatol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.
Geert D'Haens, Maria Rosario, Daniel Polhamus, Nathanael L Dirks, Chunlin Chen, William J Sandborn

Expert Rev Clin Pharmacol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Silvio Danese, Remo Panaccione, Brian G Feagan, Anita Afzali, David T Rubin, William J Sandborn

Lancet Gastroenterol Hepatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial.
Vipul Jairath, Guangyong Zou, Zhongya Wang, Shashi Adsul, Jean-Frederic Colombel, William J Sandborn

BMJ Open Gastroenterol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1.
William J Sandborn, Bruce E Sands, Sharif Uddin, Rana M Qasim Khan, Richa Sagar Mukherjee

Crohns Colitis 360· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Laurent Peyrin-Biroulet, Jessica R Allegretti, David T Rubin, Brian Bressler, Matthew Germinaro, William J Sandborn

Gastroenterology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pangenome comparison of genomospecies unveil genetic diversity and ecological insights.
Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, Chia-Yun Hsu, Caitlin Tribelhorn, William J Sandborn

bioRxiv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease.
Brian G Feagan, William J Sandborn, Bruce E Sands, Yan Liu, Marion Vetter

J Patient Rep Outcomes· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis